No abstract

No abstract

background:Platelets play a key role in the pathophysiology of acute myocardial infarction. There is evidence that higher platelet volumes may have increased prothrombotic potential. The aim of this study was to evaluate whether mean platelet volume can predict culprit coronary vessel flow and adverse cardiovascular outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Methods: Primary endpoint was the composite of adverse cardiovascular events (death, stroke, myocardial infarction, stent thrombosis, class-III or IV angina and heart failure) at 30 days. The secondary endpoint was evaluated by the angiographic TIMI flow grade after the procedure. results: Of the 215 patients included in the primary percutaneous coronary intervention registry, 168 (78.6%) had their mean platelet volume calculated before the procedure and were analyzed in the present study. Mean platelet volume values were stratified in tertiles, and a high value was considered as > 11 femtoliters (fL). Mean platelet volume > 11 fL was an independent predictor of cardiovascular events at 30 days (p = 0.02). It was observed that patients with final TIMI flow grade zero or 1 showed a trend towards higher mean platelet volume compared with those with final TIMI flow 2 or 3 (11.3 ± 0.9 fL vs. 10.5 ± 1.3 fL; p = 0.06). Conclusions: Baseline mean platelet volume is a simple, useful, and easy to measure marker to predict the risk of cardiovascular events at 30 days in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Future studies may answer whether more aggressive antithrombotic therapy results in better angiographic and/or clinical outcomes in patients with larger and more active platelets.

Introduction:Early reperfusion therapy is crucial in patients with ST-elevation myocardial infarction (STEMI). Off-hours hospital presentation may increase the time from pain to coronary reperfusion, and it may be responsible for increased cardiovascular outcomes. The aim of this study was to compare the effect of different times of presentation (on-and off-hours) on early mortality and major cardiovascular outcomes in patients with STEMI who underwent primary percutaneous coronary intervention (PCI). Methods:We have included consecutive patients with STEMI who underwent primary PCI between April 2011 and November 2016 in a tertiary university hospital in southern Brazil. Patients were divided into on-and off-hours admission. In-hospital and 30-day outcomes were evaluated. Results:A total of 301 patients (57.4%) were admitted during off-hours, and 223 (42.5%) during on-hours. Baseline characteristics were well balanced between the two groups. Median door-to-balloon time was higher in the off-hours group than in the on-hours group: 75 min (IQR 60-95) vs. 60 min (IQR 50-73.7) respectively (p < 0.001). In-hospital mortality was similar between groups (odds ratio [OR] = 0.56; 95% confidence interval [95%CI] 0.31-1.03; p = 0.06) and at 30-day follow-up (OR = 0.2; 95%CI 0.02-1.72 p = 0.14). In the matched cohort, no difference was found in the rates of in-hospital mortality (OR = 2.0; 95%CI 0.75-5.32; p = 0.16) and 30-day MACE (OR= 0.9; 95%CI 0.49-1.66; p = 0.75). Conclusions:In our center with PCI available 24/7 -without in-house staff -we did not observe any difference in patient characteristics, management, and outcomes, although a significant longer door-to-balloon time was found in patients treated during night shifts. Our results are consistent with those of other trials.

Background: Data on the management and prognosis of patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease are limited in Brazil, showing that the available revascularization strategies should be investigated Objective: To assess the outcomes of complete revascularization versus treatment of the culprit artery only in patients with STEMI and multivessel disease. Methods: A prospective cohort study was conducted at two medical centers in southern Brazil with a 1-year follow-up after the index procedure. The primary outcome was a composite of cardiac death, reinfarction, or recurrent angina, while the secondary outcome was stroke, nonfatal cardiac arrest, major bleeding, or need for reintervention. The probability of outcomes occurring was compared between the groups using binary logistic regression. A p-value < 0.05 was considered statistically significant. Results: Eighty-five patients were included. Their mean age was 62±12 years, and 61 (71.8%) were male. Fifty-eight (68.2%) were treated with complete revascularization and 27 (31.8%) with incomplete revascularization. The chance of both the primary and secondary outcomes occurring was significantly greater among patients treated with incomplete revascularization when compared to those treated with complete revascularization (odds ratio [OR] 5.1, 95% confidence interval [CI] 1.6-16.1 vs. OR 5.2, 95% CI 1.2-22.9, respectively), as well as cardiac death (OR 6.4, 95% CI 1.2-35.3). Conclusion: Registry data from two centers in southern Brazil demonstrate that the complete revascularization strategy is associated with a significant reduction in primary and secondary outcomes in a 1-year follow-up when compared to the incomplete revascularization strategy (Arq Bras Cardiol. 2020; 115(2):229-237

Introduction: Cardiac involvement in COVID-19 can range from mild damage to severe myocarditis. The precise mechanism by which COVID-19 causes myocardial injury is still unknown. Myocarditis following administration of COVID-19 vaccines, especially those based on mRNA, has also been described. However, no reports of heart failure following reinfection with COVID-19 in patients immunized with an inactivated vaccine have been identified. Case description : Male, 47-year-old, of African descent, construction worker, with type II diabetes, with a history of infection by SARS-CoV-2 in December 2020 and May 2021, confirmed by RT-PCR. Received two doses of an inactivated vaccine against COVID-19. Between the two COVID-19 episodes with positive RT-PCR he had two episodes of bacterial lung infection. After the second episode of SARS-CoV-2 infection, he was diagnosed with severe heart failure as a sequelae of myocarditis. Conclusion: It is essential to do a proper follow-up after infection by SARS-CoV-2, since even with proper immunization, there is a possibility that the patient was reinfected and had severe cardiac sequelae as a consequence, and the hypothesis of an etiology associated with the use of an inactivated vaccine against COVID-19 with a potential immune enhancement mechanism following re-infection with SARS-CoV-2 cannot be rejected.

We here report a case of ST-elevation myocardial infarction (STEMI) due to simultaneous acute coronary artery occlusions of two major coronary arteries in a patient with coronary ectasia. The patient had been previously submitted to percutaneous coronary angioplasty with bare metal stent implantation in both culprit vessels. Very late stent thrombosis could be the cause of the first occlusion, triggering the event in the other vessel. In addition, concomitant embolic sources were not identified. Although routine aspiration thrombectomy in STEMI was not proven to be beneficial in randomized clinical trials, it was of great value in this case. We also discuss the relation between coronary ectasia, chronic inflammatory status, and increased platelet activity which may have caused plaque disruption in another already vulnerable vessel.

No abstract